REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...
This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...
